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Fig1B. 6 months follow-up radiograph depicts deﬁnite medial joint space
narrowing (JSN; arrows) with persistent absence of osteophytes medially
consistent with RPOA.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A359by EPS and ADWB. CAP did not improve ADWB or EPS. These results are
different than those found in mice with acute inﬂammatory arthritis that
were pretreatedwith vanilloids. SP expression in theDRG of arthriticmice
was increased compared to naïve but IA treatment with CAP normalized
this expression. The use IA RTX or CAP for analgesia in chronic inﬂam-
matory arthritis will require additional consideration of optimal dose and
timing of administration which has yet to be determined.
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Purpose: Monoclonal antibodies that bind and inhibit nerve growth
factor (NGF) have demonstrated both good analgesic efﬁcacy and
improvement in function in patients with osteoarthritis (OA). Anti-(a)
NGF therapies offer potential as the ﬁrst new class of analgesics for
many years. Despite promising efﬁcacy data, trials in OA were sus-
pended due to concerns over accelerated rates of OA progression inFig 1A. Baseline radiograph shows a normal medial and lateral joint space
width.some patients. However, continued development of aNGF drugs with
rigorous safety screening criteria in future trials is planned and imaging
will play a crucial role. Imaging will be used to deﬁne the eligibility of
potential participants and to monitor safety during the course of these
studies in order to identify subjects at risk for rapidly progressive OA
(RPOA) prior to inclusion or to withdraw subjects from treatment early
due to the occurrence of joint safety events such as RPOA.
The aim of this presentation is to describe and illustrate MRI and
radiographic imaging ﬁndings that will be important for patient eligi-
bility and safety monitoring in planned studies of aNGF compounds.
Methods: This illustrative presentation is based on repetitive meetings
of four experienced musculoskeletal radiologists to deﬁne potentialFig 2. Coronal T1 weighted MR image shows typical metaphyseal osteo-
necrosis (arrows) with central fat-like signal (asterisk).
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A360eligibility and safety ﬁndings relevant for aNGF clinical trials. More than
400 images were reviewed to deﬁne the most relevant and character-
istic imaging ﬁndings.
Diagnoses of exclusion for eligibility due to potentially increased risk of
RPOA are subchondral insufﬁciency fractures (SIF), atrophic OA and
severe malalignment of the knee in the medial-lateral direction. Diag-
noses relevant for safety after enrolment (i.e. joint safety ﬁndings), i.e.
RPOA, SIF, osteonecrosis and pathologic fractures will also be discussed.
Several of these diagnoses have non-speciﬁc ﬁndings on the radiograph
or cannot be detected radiographically in early stages. Thus, in cases of
inconclusive or suspicious radiography, an additional MRI examination
may be acquired to rule out or conﬁrm some of these diagnoses.
Results: Early and late signs of diagnoses relevant for eligibility will be
presented.
Fig 3A. Radiograph of the hip joint shows superior JSN (arrows) without
relevant osteophytes present.Fig 3B. Follow up image 12 months later shows near-complete destruc-
tion of the femoral head (arrows) and subsequent migration of the femur
superiorly consistent with RPOA.
Conclusions: Expert readers in aNGF programs need to be aware of
relevant imaging ﬁndings. These include early signs of diagnoses rele-
vant for RPOA on radiography, and other potential X-ray and MRI
diagnoses relevant for eligibility and safety during aNGF studies.
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Purpose: Although available intra-articular (IA) corticosteroids are well
established in the treatment of painful osteoarthritis (OA), limitations
include short duration of pain relief (1-4 weeks), an effect consistent
with the transient residency of these compounds in the joint and high
plasma corticosteroid concentrations immediately following injection.
FX006 is a novel IA sustained-release injectable formulation of 25%
triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid) micro-
spheres intended to prolong therapeutic concentrations of TCA in the
joint and limit systemic exposure. In a previously described 6-week
long clinical study, FX006 at 40 mg demonstrated maintenance of
synovial concentrations of TCA consistent with pharmacologic activity
for a period of at least 6 weeks, when levels of TCA produced by an
equivalent dose of TCA IR were below the limit of quantitation. The
current study extended these data on joint residency by measuring
synovial ﬂuid levels of TCA at later time points.
Methods: In this multi-center, open-label study, patients with OA of the
knee received a single IA injection of FX006 containing 10 or 40mg TCA,
or 40mg of a standard, immediate-release suspension of TCA (TCA IR). A
total of 50 patients were enrolled (FX006 10 mg: 10 patients, FX006 40
mg: 30 patients, TCA IR: 10 patients). Synovial ﬂuid and plasma samples
were obtained at baseline (pre-dose) and at the planned Final Visit at
either Week 12, 16, or 20, depending on cohort assignment and avail-
ability of ﬂuid in the knee. Concentrations of TCA were measured in
plasma or in ﬁltered synovial ﬂuid samples using High Performance
Liquid Chromatographic methods with Tandem Mass Spectrometry
Detection and Automated Extraction, validated for the determination of
TCA in human plasma and synovial ﬂuid respectively. The quantitation
limits of both assays were 50 to 50000 pg/mL.
Results: In the FX006 10 mg group, 8 patients had synovial ﬂuid
available for analysis at Week 12. In the FX006 40 mg group, 6 patients
had synovial ﬂuid available for analysis at Week 12, 8 patients at Week
16 and 11 patients at Week 20. In the TCA IR group, 5 patients had
synovial ﬂuid available for analysis at Week 12. The concentrations of
TCA achieved by 40mg FX006 in the synovial ﬂuid atWeek 12 were 924
pg/mL, at Week 16, the IA concentrations of TCAwere 224 pg/mL and by
Week 20 they were below the lower limit of quantitation (Figure;
geometric means from the earlier 6-week study and the current study
are merged). The IA concentration of TCA in patients receiving 40 mg of
TCA IR at Week 12 was below the lower limit of quantitation. FX006
maintained a gradient between synovial and systemic plasma concen-
trations of TCA for 16 weeks.
